Unknown PHASE1 INTERVENTIONAL 2-arm NCT04071639

Symptomatic Therapy for Patients With Huntington's Disease

Non-randomized Control Clinical Trial to Evaluate the Efficacy and Safety of Symptomatic Drug Therapy for Mild to Moderate Huntington's Disease Patients

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Conditions Huntington Disease

Interventions Deutetrabenazine Oral Tablet [Austedo] Haloperidol 2Mg Tab Idebenone Risperidone 1Mg Tab Zoloft 50Mg Tablet

Updated 7 times since 2019 Last updated: Mar 30, 2021 Started: Mar 12, 2020 Primary completion: Dec 31, 2024 Completion: Dec 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Huntington Disease and is currently ongoing. Second Affiliated Hospital, School of Medicine, Zhejiang University leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Feb 2025 — Present [monthly]

Unknown PHASE1

Status: Recruiting → Unknown
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
May 2021 — Jul 2024 [monthly]

Recruiting PHASE1
Jan 2021 — May 2021 [monthly]

Recruiting PHASE1

▶ Show 2 earlier versions

Oct 2019 — Jan 2021 [monthly]

Recruiting PHASE1
Sep 2019 — Oct 2019 [monthly]

Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Second Affiliated Hospital, School of Medicine, Zhejiang University

Data source: Second Affiliated Hospital, School of Medicine, Zhejiang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China